Controlled trial of natamycin in the treatment of allergic bronchopulmonary aspergillosis.
نویسندگان
چکیده
Allergic bronchopulmonary aspergillosis often requires treatment with oral corticosteroids to control the host response to Aspergillus fumigatus. In a double blind study 25 patients with allergic bronchopulmonary aspergillosis taking maintenance oral corticosteroids were randomly allocated to receive 5 mg natamycin or placebo by nebuliser twice daily for one year. The primary aim of the study was to assess the steroid sparing potential of natamycin. Standardised reductions in corticosteroid dosage were therefore undertaken every five weeks, unless clinically contraindicated. Five patients were withdrawn in the first four months: two (1 natamycin, 1 placebo) died, two (1 natamycin, 1 placebo) had suspected drug reactions, and one (natamycin) was non-compliant. The pretreatment characteristics of the 20 patients (10 in each group) who completed the study were similar, 17 (9 natamycin, 8 placebo) having evidence of recent disease activity. At the end of the study prednisolone dose had been reduced by a similar amount in each group (median natamycin 2.25 mg, placebo 2.5 mg). Evidence of disease activity during the study year (transient shadowing on the chest radiograph, blood eosinophilia, or increases in antibodies to A fumigatus, or any combination of these) was observed in similar numbers of patients in each group (5 natamycin, 7 placebo). There was no evidence that natamycin conferred benefit on these patients with allergic bronchopulmonary aspergillosis.
منابع مشابه
Proficiency testing of first- and second-line anti-tuberculosis drugs in Italy.
bronchopulmonary aspergillosis. Ann Allergy Asthma Immunol 1999; 82: 511–516. 4 Salez F, Brichet A, Desurmont S, et al. Effect of itraconazole therapy in allergic bronchopulmonary aspergillosis. Chest 1999; 116: 1665–1668. 5 Montoya JG, Chaparro SV, Celis D, et al. Invasive aspergillosis in the setting of cardiac transplantation. Clin Infect Dis 2003; 37: 281–292. 6 Rijnders BJ, Cornelissen JJ,...
متن کاملT Helper 2 Cytokine Analysis of Bronchoalveolar Lavage in the Murine Model of Allergic Broncho Pulmonary Aspergillosis
Background and Aims: Aspergillus fumigatus is a sporadic fungus that causes different infections and allergies in immunocompromised patients. The allergic disease caused by this fungus is called allergic bronchopulmonary aspergillosis (ABPA). ABPA is considred important in atopic and immunocompromised individuals, which can result in inflammation and epithelial damage. Therefore, the aim of thi...
متن کاملElevated levels of exhaled nitric oxide in recurrent tonsillitis.
REFERENCES 1 Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis – state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003; 37: Suppl. 3, S225–S264. 2 Skowronski E, Fitzgerald DA. Life-threatening allergic bronchopulmonary aspergillosis in a well child with cystic fibrosis. Med J Aust 2005; 182: 482–483. 3 Skov M, Main...
متن کامل[Prolonged therapeutic response to voriconazole in a case of allergic bronchopulmonary aspergillosis].
Allergic bronchopulmonary aspergillosis is a lung disease characterized by an immune response to several antigens of Aspergillus species. Corticosteroids are the treatment of choice in the acute phase, although some studies have shown the efficacy of itraconazole. We describe the case of a favorable, prolonged therapeutic response to voriconazole in a patient with allergic bronchopulmonary aspe...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Thorax
دوره 45 6 شماره
صفحات -
تاریخ انتشار 1990